Quoin Pharmaceuticals, Ltd. American Depositary Shares (QNRX) is a publicly traded Healthcare sector company. As of May 21, 2026, QNRX trades at $5.06 with a market cap of $11.11M and a P/E ratio of 0.00. QNRX moved +0.00% today. Year to date, QNRX is -64.84%; over the trailing twelve months it is -38.17%. Its 52-week range spans $4.80 to $54.95. Analyst consensus is strong buy with an average price target of $35.00. Rallies surfaces QNRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Quoin Pharmaceuticals Earns FDA Fast Track, MHLW Orphan Designations, Targets 2027 NDA: Quoin Pharmaceuticals secured Fast Track Designation from the FDA for QRX003 lotion (4%) and obtained Orphan Drug Designation plus Fast Track review qualification from Japan's MHLW for Netherton Syndrome. The company also filed for Breakthrough Medicine Designation in Saudi Arabia, expects Phase 3 recruitment by end-2026 and NDA filing in 2027.
| Metric | Value |
|---|---|
| Price | $5.06 |
| Market Cap | $11.11M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $54.95 |
| 52-Week Low | $4.80 |
| Volume | 10 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-15.80M |
| Gross Margin | 0.00% |
3 analysts cover QNRX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.00.